Global Cell & Gene Therapy Cold Chain Logistics Market Outlook, 2024-2029: Surge in Collaborations and Patient-Centric Logistics for Personalized Therapies Driving the Market at 14.1% CAGR

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapy Cold Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F" report has been added to's offering.

The Global Cell & Gene Therapy Cold Chain Logistics Market is expected to experience significant growth, with a projected CAGR of 14.11% through 2029, commencing from a valuation of USD 1.68 billion in 2023. This industry's advancement is predominantly driven by the burgeoning demand for personalized medicine and cutting-edge progressions in biotechnology. The increasing prevalence of cell and gene therapy applications in treating a manifold of diseases necessitates the augmented need for meticulous cold chain logistics to ensure the preservation of these therapies’ efficacy and safety.

The accelerating growth can be attributed to several market drivers, including the escalated demand for personalized medicine and the surge of technological advancements in biotechnology. As regulatory approvals proliferate and the healthcare infrastructure continues to expand, especially in emerging economies, the cold chain logistics market for cell and gene therapies is anticipated to broaden considerably. These factors, along with the need for stringent temperature control and comprehensive supply chain management, outline the key areas contributing to the market's expansion.

Despite vigorous growth, the market confronts challenges in maintaining stringent temperature control and navigating complex and fragmented supply chains. Overcoming these hurdles is pivotal to preserving the integrity of these highly sensitive biological materials. Furthermore, current trends indicate an increase in collaborations and partnerships within the market, as well as a patient-centric approach that demand logistical excellence in delivering personalized therapies.

Segmental Insights

Intricate component analysis reveals that cryogenic shippers currently dominate the market, attributable to their critical role in sustaining ultra-low temperatures required for cell and gene therapy products. With transportation services being crucial for efficient logistics, it remains a dominant force in the services offered segment.

Regional Developments

Regionally, North America, particularly the United States, is spearheading the global market, attributed to its leadership in innovation and comprehensive regulatory frameworks. The region’s robust infrastructure and adherence to top-notch distribution practices stand as the cornerstone for its dominance in the cell gene therapy cold chain logistics market.

Competitive Landscape

The competitive landscape sees key players involved in the cell and gene therapy cold chain logistics market assertively working on expanding their global footprint and augmenting their capabilities to cater to the increasing market demands.

Key Attributes

Report AttributeDetails
No. of Pages183
Forecast Period2023-2029
Estimated Market Value (USD) in 2023$1.68 Billion
Forecasted Market Value (USD) by 2029$3.71 Billion
Compound Annual Growth Rate14.1%
Regions CoveredGlobal

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Global Cell & Gene Therapy Cold Chain Logistics Market

Contact Data